Post-OTC Review Conditions Covered Under Proposed Monograph Procedures
This article was originally published in The Rose Sheet
Executive Summary
Companies seeking monograph status of OTC drugs marketed in the U.S. after the beginning of the OTC review may be required to follow FDA's proposed new procedures for additional OTC conditions.